Cleary M L, Warnke R, Sklar J
N Engl J Med. 1984 Feb 23;310(8):477-82. doi: 10.1056/NEJM198402233100801.
Whether lymphoproliferative disorders arising in immunosuppressed recipients of organ transplants are primarily neoplastic or hyperplastic in nature is a matter of controversy. Reports of polyclonal B-cell proliferations in these lesions suggest the presence of hyperplasia, but these disorders resemble lymphoma histologically and are clinically aggressive and often rapidly fatal, as expected of a malignant neoplastic disease. We examined tissue specimens from 10 cases of lymphoproliferative disease that occurred in immunosuppressed recipients of cardiac transplants. Specimens from nine of these patients lacked cellular immunoglobulin; however, analysis of DNA extracted from these tissues revealed that each lesion contained large numbers of cells possessing uniform, clonal rearrangements of immunoglobulin-gene DNA. Therefore, when first seen clinically these proliferations contained a notable monoclonal-cell population typical of conventional B-cell lymphomas that are not associated with immunosuppression. We therefore suggest that lymphoproliferative disorders in recipients of cardiac transplants are neoplastic at the earliest stages of detectable disease.
器官移植免疫抑制受者中出现的淋巴增殖性疾病本质上主要是肿瘤性的还是增生性的,这是一个有争议的问题。这些病变中多克隆B细胞增殖的报告提示存在增生,但这些疾病在组织学上类似于淋巴瘤,并且在临床上具有侵袭性,通常会迅速致命,这正如恶性肿瘤性疾病所预期的那样。我们检查了10例发生在心脏移植免疫抑制受者中的淋巴增殖性疾病的组织标本。其中9例患者的标本缺乏细胞免疫球蛋白;然而,对从这些组织中提取的DNA的分析显示,每个病变都含有大量具有免疫球蛋白基因DNA均匀、克隆重排的细胞。因此,在临床上首次发现时,这些增殖包含典型的传统B细胞淋巴瘤的显著单克隆细胞群,而这些淋巴瘤与免疫抑制无关。因此,我们认为心脏移植受者中的淋巴增殖性疾病在可检测疾病的最早阶段就是肿瘤性的。